Edwards Lifesciences (NYSE:EW) Upgraded at Dbs Bank

Dbs Bank upgraded shares of Edwards Lifesciences (NYSE:EW) to a hold rating in a report published on Monday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a report on Friday, April 25th. Robert W. Baird raised their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a report on Thursday, April 24th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Piper Sandler raised their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, May 13th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $80.20.

Edwards Lifesciences Trading Up 0.3%

Shares of Edwards Lifesciences stock opened at $77.95 on Monday. The firm has a market capitalization of $45.73 billion, a PE ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $95.25. The firm’s 50-day moving average price is $73.76 and its 200 day moving average price is $72.64.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.66 EPS. On average, sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares of the company’s stock, valued at $1,569,414.24. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,012 shares of company stock valued at $4,224,717 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $610,895,000. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $330,881,000. Raymond James Financial Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $213,844,000. Finally, Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.